Estimation of TNF- α and some immunological parameters in patient with systemic lupus erythematosus
DOI:
https://doi.org/10.32792/utq/utjsci/v11i2.1197Keywords:
SLE,TNF α,immunological parametersAbstract
Abstract:
Abstract— Systemic Lupus Erythematosus (SLE) is a multifactorial chronic systemic autoimmune disease. It is characterized by a lack of immune tolerance to autoantigens such as nuclear antigens. In this study, 25 individuals diagnosed with SLE had their blood samples drawn, while 25 healthy individuals were used as a control group. The results of this investigation show that the patients' TNF-α levels (106.9 ± 10.8) significantly increased more than 52.86 in the control group. Comparing the immunological parameters of the patients to the healthy group, the study revealed a decrease in the eosinophile, basophile, lymphocyte, and monocyte counts (010 ± 0.003, 0.022 ± 0.004, 1.71 ± 0.66, 0.21 ± 0.047 respectively) and a rise in the neutrophile and immature granulocyte counts (7.43 ± 1.66, 2.68 ± 0.46 respectively) in SLE patient.
Keywords— SLE,TNF‑α,immunological parameters
13-3-2024
19-3-2024
29-4-2024
References
[1] B. Sojod, C. Pidorodeski Nagano, G. M. Garcia Lopez, A. Zalcberg, S. M. Dridi, and F. Anagnostou, "Systemic lupus erythematosus and periodontal disease: a complex clinical and biological interplay," Journal of Clinical Medicine, vol. 10, no. 9, p. 1957, 2021.
[2] K. Horst et al., "Antigen presentation, autoantibody production, and therapeutic targets in autoimmune liver disease," Cellular & Molecular Immunology, vol. 18, no. 1, pp. 92-111, 2021.
[3] J. Mucke et al., "LUPUS-BEST—treat-to-target in systemic lupus erythematosus: study protocol for a three-armed cluster-randomised trial," Lupus Science & Medicine, vol. 8, no. 1, p. e000516, 2021.
[4] B. Dema and N. Charles, "Advances in mechanisms of systemic lupus erythematosus," Discovery Medicine, vol. 17, no. 95, pp. 247-255, 2014.
[5] A. Bag-Ozbek and J. S. Hui-Yuen, "Emerging B-cell therapies in systemic lupus erythematosus," Therapeutics and clinical risk management, pp. 39-54, 2021.
[6] F. Fanouriakis, N. Tziolos, G. Bertsias, and D. T. Boumpas, "Update on the diagnosis and management of systemic lupus erythematosus," Annals of the Rheumatic Diseases, vol. 80, no. 1, pp. 14-25, 2021.
[7] T. Koga et al., "The role of IL-17 in systemic lupus erythematosus and its potential as a therapeutic target," Expert Review of Clinical Immunology, vol. 15, no. 6, pp. 629-637, 2019.
[8] D. Y. H. Yap and K. N. Lai, "Cytokines and their roles in the pathogenesis of systemic lupus erythematosus: from basics to recent advances," BioMed Research International, vol. 2010.
[9] A. Sabry et al., "Proinflammatory cytokines (TNF-α and IL-6) in Egyptian patients with SLE: its correlation with disease activity," Cytokine, vol. 35, no. 3-4, pp. 148-153, 2006.
[10] F. Ghorbaninezhad et al., "Tumor necrosis factor α in systemic lupus erythematosus: Structure, function and therapeutic implications," International Journal of Molecular Medicine, vol. 49, no. 4, pp. 1-13, 2022.
[11] D. S. Pisetsky, "Anti-DNA and autoantibodies," Current Opinion in Rheumatology, vol. 12, no. 5, pp. 364-368, 2000.
[12] S. Al-Mutairi, A. Al-Awadhi, R. Raghupathy, H. Al-Khawari, P. Sada, A. Al-Herz, and P. Rawoot, "Lupus patients with pulmonary involvement have a pro-inflammatory cytokine profile," Rheumatology International, vol. 27, pp. 621-630, 2007.
[13] V. Umare et al., "Effect of proinflammatory cytokines (IL-6, TNF-α, and IL-1β) on clinical manifestations in Indian SLE patients," Mediators of Inflammation, vol. 201.
[14] M. A. Gill et al., "Blood dendritic cells and DC-poietins in systemic lupus erythematosus," Human Immunology, vol. 63, no. 12, pp. 1172-1180, 2002.
[15] K. Palucka et al., "The interplay of dendritic cell subsets in systemic lupus erythematosus," Immunology and Cell Biology, vol. 80, no. 5, pp. 484-488, 2002.
[16] M. Aringer and J. S. Smolen, "SLE-complex cytokine effects in a complex autoimmune disease: tumor necrosis factor in systemic lupus erythematosus," Arthritis Res Ther, vol. 5, pp. 1-6, 2003.
[17] Z. Yang et al., "Comparisons of neutrophil‐, monocyte‐, eosinophil‐, and basophil‐lymphocyte ratios among various systemic autoimmune rheumatic diseases," Apmis, vol. 125, no. 10, pp. 863-871, 2017.
[18] B. K. Han et al., "Neutrophil and lymphocyte counts are associated with different immunopathological mechanisms in systemic lupus erythematosus," Lupus Science & Medicine, vol. 7, no. 1, 2020.
[19] V. Brinkmann et al., "Neutrophil extracellular traps kill bacteria," Science, vol. 303, no. 5663, pp. 1532-1535, 2004.
[20] C. Lood et al., "TLR7/8 activation in neutrophils impairs immune complex phagocytosis through shedding of FcgRIIA," Journal of Experimental Medicine, vol. 214, no. 7, pp. 2103-2119, 2017.
[21] K. Dossybayeva, D. Abdukhakimova, and D. Poddighe, "Basophils and systemic lupus erythematosus in murine models and human patients," Biology, vol. 9, no. 10, 2020.
[22] F. Bashal, "Hematological disorders in patients with systemic lupus erythematosus," The Open Rheumatology Journal, vol. 7, p. 87, 2013.
[23] G. Steinbach, P. M. Lynch, R. K. Phillips, M. H. Wallace, E. Hawk, G. B. Gordon, et. al., "The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis", 2000 Jun 29;342(26):1946-52.
Downloads
Published
License
Copyright (c) 2024 University of Thi-Qar Journal of Science
This work is licensed under a Creative Commons Attribution 4.0 International License.
